

# Oregon Prescription Drug Monitoring Program 2020 2nd Quarter Report


Percentage change evaluated relative to 2nd Quarter, 2019

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



## Summary

- Registration has increased over the last year in all prescriber types (DDS/DMD, +12.1%; NP, +14.8%; MD/PA/DO, +11.1%; ND, +16.0%), pharmacists (+42.5%) and delegates (+26.6%) (Table 4). New registration continues among prescribers and pharmacists, likely driven by health systems' registration efforts prior to PDMP integration.
- Web queries have decreased by 24.0% from the 2nd quarter of 2019; pharmacists (-38.1%), healthcare providers (-18.7%), and delegates (-17.8%) (Table 3).
- Integrated queries have increased dramatically across all clinical user groups except dentists; Pharmacists (+24.4%), ND (+57.1%), MD/PA/DO (+138.2%), NP/CNS-PP (+72.3%), DDS/DMD (-25.0%) (Table 4).
- Prescriptions for opioids continued to trend downward (hydrocodone, -14.6%; oxycodone, -10.6%), while amphetamine increased (+6.8%); methylphenidate (-7.9%) and common benzodiazepines such as lorazepam (-3.4%), alprazolam (-7.1%) and clonazepam (-2.9%) decreased (Table 5).
- Prescriptions have increased for buprenorphine (+29.7%) and naloxone (+36.9%), but have decreased for buprenorphine/naloxone combinations (-5.9%) (Table 6).



† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2020 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2019

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



**Table 1. PDMP Queries Summary Statistics: April – June, 2020**

Measure	Web Portal	% Change*	Integrated	% Change*
Queries †	292,737	- 24.0 %	4,388,635	+ 112.5%
Healthcare providers	76,345	- 18.7 %	3,602,950	+ 88.4%
Pharmacies	70,272	- 38.1 %	785,685	+ 415.6%
Delegates	146,018	- 17.8 %	0	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- Integrated Query data indicates that the number of integrated queries from healthcare providers and pharmacists has increased dramatically over the same quarter last year.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

**Table 2. Special Requests: April – June, 2020**

Measure	Count
Special Requests Total	108
Patient Records	7
Healthcare Board	101
Law Enforcement	7

- 108 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

\* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxRxE web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

# Oregon Prescription Drug Monitoring Program 2020 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2019

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



**Table 3. PDMP Enrollment and System Use: April – June, 2020**

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
<b>All Prescribers</b>	17,671	15,096 / 85.4 %	6,120 / 40.5 %	2,679 / 17.7 %	7,309 / 48.4 %
<b>Top 4K Prescribers</b>	4,000	3,876 / 96.9 %	2,553 / 65.9 %	1,253 / 32.3 %	2,888 / 74.5 %
<b>Top 2K Prescribers</b>	2,000	1,965 / 98.3 %	1,416 / 72.1 %	666 / 33.9 %	1,562 / 79.5 %

- During the 2nd quarter of 2020 there were 17,671 prescribers who wrote prescriptions for controlled substances in Oregon.
- Registration for the PDMP has increased among all prescribers and especially among frequent prescribers reflecting the impact of mandatory registration.
- In quarter two 48.4 % of enrolled prescribers queried the system; 74.5 % of the top 4,000 prescribers; 79.5 % of the top 2,000 prescribers.

**Table 4. PDMP Query by Clinical User Group: April – June, 2020**

Discipline	Total User Accounts	% Change*	Web Users <sup>±†</sup>	% Change*	Integrated Users	% Change*
MD/PA/DO	17,063	+ 11.1 %	1,878	- 33.3 %	16,842	+ 138.2 %
NP/CNS-PP	3,975	+ 26.6 %	941	- 11.9 %	834	+ 72.3 %
RPh	3,756	+ 14.8 %	1,585	- 16.5 %	694	+ 24.4 %
Delegates	3,351	+ 42.5 %	2,043	- 22.8 %	0	-
DDS/DMD	2,853	+ 12.1 %	379	- 25.0 %	45	- 25.0 %
ND	588	+ 16.0%	156	- 3.1 %	33	+ 57.1 %

- PDMP registration has increased among all prescriber groups, pharmacists and delegates.
- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing across all groups.
- Integrated Users have increased over the past year across all clinical groups with the exception of dentists.

\* Percentage change figures evaluated relative to the same time period during the prior year.

<sup>±</sup> Users that have submitted a query this quarter.

<sup>†</sup> Query data drawn from Appriss AWAxRxE and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2020 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2019

healthoregon.org/pdmp



Table 5. Top Prescriptions: April – June, 2020

Drug	# of Rx	% of all Rx	% Change*
All	1,599,441	100.0 %	+ 6.6 %
Hydrocodone	230,925	14.4 %	- 14.6 %
Gabapentin	218,704	13.7 %	-
Oxycodone	207,894	13.0 %	- 10.6 %
Amphetamine	164,517	10.3 %	+ 6.8 %
Tramadol	81,320	5.1 %	- 6.9 %
Lorazepam	80,306	5.0 %	- 3.4 %
Zolpidem	67,831	4.2 %	- 10.1 %
Methylphenidate	65,711	4.1 %	- 7.9 %
Alprazolam	61,632	3.9 %	- 7.1 %
Clonazepam	61,376	3.8 %	- 2.9 %

- The number of prescriptions for opioid and benzodiazepine medications continues to decrease relative to the same quarter last year.
- Prescriptions for stimulants, including amphetamine, methylphenidate and pseudoephedrine, increased relative to the same quarter last year.
- Prescriptions for gabapentin surged reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

Table 6. Prescriptions for Buprenorphine and Naloxone: April – June, 2020

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	36,592	2.3 %	+ 29.7 %
Buprenorphine/Naloxone	23,432	1.5 %	- 5.9 %
Naloxone	4,327	0.3 %	+ 36.9 %

- Prescriptions for buprenorphine and naloxone have increased while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, [pdmp.research@state.or.us](mailto:pdmp.research@state.or.us)

\* Percentage change figures evaluated relative to the same time period during the prior year